Topic: Julie Gerberding

The discussion shifts to high-level CDC officials, specifically Dr. Julie Gerberding and Colleen Boyle, who are accused of facilitating fraudulent studies. Grundvig notes that Gerberding transitioned from the CDC to a leadership role at Merck, while Boyle remains at the CDC despite her controversial history with Agent Orange studies. There is an expressed hope that the Donald Trump administration will take action against these individuals.

The timeline of Dr. Julie Gerberding’s departure from the CDC to Merck is linked to the discovery of Poul Thorsen’s embezzlement. Grundvig explains how Thorsen managed to continue working at various universities, including Drexel and Johns Hopkins, even after his resignation from Aarhus University. Despite the outstanding warrant for his arrest, Thorsen reportedly continues to receive funding and recognition for scientific studies.

The discussion focuses on Julie Gerberding, the former head of the CDC who oversaw the period of the alleged MMR fraud and later became president of Merck's vaccine division. Rappaport points out the blatant conflict of interest, as Merck manufactures the very vaccines Gerberding was responsible for regulating. He compares Merck to Monsanto, describing them as the dominant, aggressive force in the pharmaceutical industry.